Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986259 in acute decompensated heart failure
NCT04318093Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2020
- Primary completion
- Jul 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing BMS-986259 with Placebo (2 arms). Primary endpoint: Percentage of Participants Experiencing Clinically Relevant Hypotension at 30 days. Started Nov 2020; status: completed.
02
Drugs
FA relaxin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04318093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318093.